FierceBiotech 30. Jan. 2026 Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
FierceBiotech 29. Jan. 2026 Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact
FierceBiotech 29. Jan. 2026 Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
FierceBiotech 29. Jan. 2026 Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
FierceBiotech 29. Jan. 2026 Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor
FierceBiotech 29. Jan. 2026 AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
FierceBiotech 29. Jan. 2026 Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B
FierceBiotech 28. Jan. 2026 Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says
FierceBiotech 28. Jan. 2026 New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill
FierceBiotech 28. Jan. 2026 Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M
FierceBiotech 28. Jan. 2026 Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss
FierceBiotech 28. Jan. 2026 Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report
FierceBiotech 28. Jan. 2026 CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern'